BPC-157 (Body Protection Compound-157)
Overview
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a stable protein fragment found in gastric juice. It has been studied extensively in preclinical models of tissue repair — tendon and ligament healing, gastrointestinal-mucosa protection, wound healing and neuroprotection — and is notable among peptides for showing activity by the oral route in animal studies. It is a research compound; the evidence base is overwhelmingly preclinical.
Chemical Profile
| Property | Value |
|---|---|
| CAS number | 137525-51-2 |
| Class | Stable gastric pentadecapeptide |
| Amino-acid sequence | H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH |
| One-letter code | GEPPPGKPADDAGLV |
| Molecular formula | C₆₂H₉₈N₁₆O₂₂ |
| Molecular weight | 1419.52 g/mol |
| Purity (HPLC) | ≥ 98% |
| Appearance | White to off-white lyophilized powder |
- Class
- Stable gastric pentadecapeptide
- Origin
- Fragment of a human gastric-juice protein
- Research status
- Extensive preclinical investigation
- Study routes
- SC, oral, intraperitoneal, topical
- Plasma half-life
- ≈ 15 min (active in tissues longer)
- Key feature
- Multi-tissue repair; notable oral activity
Mechanism of Action
BPC-157 is described in the literature as pleiotropic rather than acting on one receptor: it is studied for modulating the nitric-oxide (NO) system and angiogenic signalling at the same time, alongside effects on growth-factor expression and cell migration. This multi-pathway picture is why it appears across so many different tissue-repair models.
| Pathway | Research description |
|---|---|
| Angiogenesis | Associated with upregulation of VEGF, VEGFR2, FGF and eNOS in repair models. |
| Nitric-oxide system | Studied for modulating NO production via the eNOS and nNOS pathways. |
| Growth factors | Linked to increased EGF, TGF-β and PDGF expression. |
| Cell migration | Investigated through FAK and Src kinase signalling. |
| Anti-apoptotic tone | PI3K/Akt activation and reduced caspase activity in models. |
| Anti-inflammatory tone | Downregulation of TNF-α, IL-6 and IL-1β; upregulation of IL-10. |
Tissue-specific effects reported in the literature (research context, not therapeutic claims):
| Tissue | Studied mechanism | Reported direction |
|---|---|---|
| Tendon / ligament | Fibroblast proliferation, collagen I synthesis | Faster healing in models |
| GI mucosa | Improved blood flow, prostaglandin signalling | Protection vs NSAID-induced lesions (rodent) |
| Muscle | Myoblast proliferation, reduced fibrosis | Improved regeneration in models |
| Nervous system | Neurotrophic effects, reduced oxidative stress | Enhanced neural recovery in models |
| Skin | Keratinocyte migration, granulation tissue | Accelerated wound closure in models |
Pharmacology
| Parameter | Value |
|---|---|
| Half-life (t½) | ≈ 15 min in plasma; longer-lasting in tissues |
| Oral activity | Demonstrated in animal models (unusual for a peptide) |
| Bioavailability (SC) | ≈ 40–60% (estimated) |
| Protein binding | Moderate (albumin and tissue binding) |
| Metabolism | Proteolytic degradation (amino- / carboxypeptidases) |
| Route of administration | SC, oral, IP, topical (research settings) |
| Elimination | Renal (peptide fragments) |
Research Evidence
BPC-157 has a large preclinical (animal-model) literature and only very limited human data. The table names representative models and what they investigated; specific numerical outcomes are not restated here as claims.
| Model | Research focus | Reference |
|---|---|---|
| Rat Achilles-tendon transection | Tendon functional recovery | Sikiric P, et al. |
| Rat NSAID-gastropathy model | Gastric-mucosa protection | Sikiric P, et al. |
| Rat / mouse skin-wound models | Wound closure and angiogenesis | Seiwerth S, et al. |
| Rat spinal-cord / nerve models | Neuroprotection and recovery | Sikiric P, et al. |
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
| Reported direction / finding | Context | Reference |
|---|---|---|
| Faster tendon functional recovery vs controls | rat Achilles transection | Sikiric P et al. |
| Protection against NSAID-induced gastric lesions | rat gastropathy | Sikiric P et al. |
| Accelerated wound closure and angiogenesis | rodent wound models | Seiwerth S et al. |
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
Dosing & Reconstitution Reference
Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.
| Parameter | Reference value |
|---|---|
| Research dose range (literature) | ≈ 10–50 µg/kg daily (SC), in animal protocols |
| Reconstitution solvent | Bacteriostatic water (0.9% benzyl alcohol) |
| Reconstitution volume | 1–2 mL per vial |
| Final concentration | ≈ 2.5–5 mg/mL |
| Storage (lyophilized) | −20°C, protected from light |
| Storage (reconstituted) | 2–8°C, up to ~7 days |
| Do not use | If the solution is cloudy or contains particulates |
Safety Profile
Published observations from research studies, provided for reference only. This material is not for human or veterinary use.
| Category | Published observations |
|---|---|
| Local tolerability | Mild injection-site reactions reported |
| General tolerability | Well tolerated in animal studies, including at high oral doses |
| Cytotoxicity | No cytotoxicity observed in cell-based assays |
| Genotoxicity | Negative Ames test in reported assays |
| Interactions | Because it modulates the NO system, caution is noted around anticoagulants |
| Status | For research use only; not for human or veterinary application |
Physicochemical Properties
| Property | Value |
|---|---|
| Physical state | White to off-white lyophilized powder |
| Solubility (water) | Freely soluble (> 50 mg/mL) |
| logP (octanol/water) | ≈ −2.8 (hydrophilic) |
| Isoelectric point (pI) | ≈ 4.2 |
| pH (reconstituted) | 5.5–6.5 |
| Stability (lyophilized) | ≥ 24 months at −20°C |
Synthesis & Manufacturing
BPC-157 is produced by solid-phase peptide synthesis using Fmoc chemistry. As a 15-residue peptide with no unusual modifications, it is comparatively straightforward, with preparative HPLC bringing it to research-grade purity.
| Step | Detail |
|---|---|
| Strategy | Fmoc solid-phase peptide synthesis |
| Resin | Rink amide MBHA resin |
| Coupling | HBTU / HOBt with DIPEA in DMF |
| Deprotection | 20% piperidine in DMF |
| Cleavage | TFA / TIPS / H₂O (95 : 2.5 : 2.5) |
| Purification | Preparative RP-HPLC (C18, TFA/ACN gradient) |
- Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
- Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
- Critical quality attributes: correct molecular weight and low deletion-peptide content. No unusual residues; standard peptide QC applies.
Analytical Methods
| Method | Parameter | Typical result |
|---|---|---|
| RP-HPLC (C18, UV 214 nm) | Purity | ≥ 98% |
| HPLC retention | C18, 5–35% B over 25 min | Single main peak |
| ESI-MS (positive mode) | Identity / mass | [M+H]⁺ ≈ 1420 Da (charge +1 to +4) |
| MALDI-TOF | Mass confirmation | [M+H]⁺ ≈ 1420 Da (charge +1 to +4) |
| Amino-acid analysis | Composition | Consistent with the stated sequence |
| LC-MS (extracted ion) | Deletion-peptide impurities | Within specification |
| Karl Fischer | Water content | < 6% |
| LAL assay | Endotoxin | Within specification |
| Ion chromatography | Residual TFA | < 500 ppm |
Representative RP-HPLC purity method:
- Column: C18, 5 µm, 250 × 4.6 mm
- Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
- Gradient: 5–35% B over 25 min · Flow rate: 1.0 mL/min · Detection: UV 214 nm
- Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 1420 Da (charge +1 to +4)). No unusual residues; standard peptide QC applies.
Stability Data
Representative stability behaviour under common storage, handling and formulation conditions.
| Condition | Duration | Result |
|---|---|---|
| Lyophilized, −20°C, dark | ≥ 24 months | No significant degradation (purity > 97%) |
| Lyophilized, 2–8°C, dark | ≥ 12 months | Minimal degradation (purity > 95%) |
| Lyophilized, 25°C (accelerated) | 3 months | < 5% degradation |
| Reconstituted, 2–8°C, dark | 7–14 days | Minor degradation |
| Reconstituted, 25°C | 24–48 h | Use promptly |
| Light exposure (ICH Q1B) | 1.2 M lux·h | Generally light-stable |
| Freeze–thaw (−20°C ⇄ 25°C) | 3 cycles | Acceptable — aliquot to avoid repeats |
- Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
- Minimise freeze-thaw cycles; aliquot material used across many sessions.
- Key factor: No unusual residues; standard peptide QC applies.
Selected References
- Sikiric P, et al. Stable gastric pentadecapeptide BPC-157: a review of the studies on its healing effects. (review literature).
- Seiwerth S, et al. BPC-157 and blood-vessel / wound-healing research. (preclinical literature).
- Chang CH, et al. The promoting effect of BPC-157 on tendon fibroblasts and tendon healing. (preclinical literature).
Quality & Supply
- HPLC ≥ 98% purity with a Certificate of Analysis per batch
- Identity confirmed by LC-MS
- Research samples through to bulk, with worldwide delivery
- Custom quantities and packaging on request
Need BPC-157 — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
